We are working diligently on driving positive regulatory decisions from both FDA and Health Canada this year. In the meantime, we are actively preparing for launch, building awareness with positive real-world clinical data, corroborating the significant reduction in serious bleeding events in CABG patients on Berlinta seen in our pivotal trial, and presenting at major cardiovascular conferences.

May 14, 2025 / receipt, needs a key / Phil, CEO | earnings call 2025-05-14 | transcript 498b8d90-422f-49f9-9c92-06b0d8ecdd75 | chars 25679-26077 | segment 25

I've had the opportunity to spend significant time with our dedicated team in New Jersey, understanding the compelling value of our technology and talent, and I've spent two weeks with our European team at two medical conferences, traveling with sales reps, visiting with surgeons, and several of our distributor partners, and getting a solid understanding of our team and operations.

Nov 7, 2024 / receipt, needs a key / CEO, CEO | earnings call 2024-11-07 | transcript 3d620c1d-9136-426e-b6c7-6df4169439f3 | chars 24985-25369 | segment 24

Although not yet showing up in our numbers, we see early but encouraging signs of improvement, including more customer visits in Germany during the quarter, continued strong positive support from customers, where the feedback on lower orders in Germany have been primarily due to hospital challenges such as staffing shortages, budgets, ICU capacity, and lower numbers of severely ill patients, a significantly increased flow of positive data on cytosol across both critical care and cardiac surgery, greater in-person attendance of healthcare providers at conferences, and improved cross-functional synergy within our company based on our new therapy area vertical strategy and leadership.

Aug 2, 2022 / receipt, needs a key / Dr. Philip Chan, CEO | earnings call 2022-08-02 | transcript f199525d-4459-4320-bff4-28f0bf293ead | chars 5627-6317 | segment 5